By Fineline Cube 
Liaocheng University and Shanghai Maiboxing Biotechnology Co., Ltd. have signed a cooperation agreement totaling RMB 19 million to jointly advance the collaborative R&D and industrialization of LCUGZ1007, a next‑generation E‑PDC (Enhanced Probody Drug Conjugate) drug.
Deal Milestone
| Item | Detail |
|---|---|
| Parties | Liaocheng University & Shanghai Maiboxing Biotechnology Co., Ltd. |
| Agreement Type | Cooperation agreement — joint R&D and industrialization |
| Total Value | RMB 19 million |
| Asset | LCUGZ1007 — next‑generation E‑PDC (Enhanced Probody Drug Conjugate) |
| Current Stage | Systematic preclinical evaluation completed |
| Development Goal | Enter clinical trial stages as soon as possible |
Technology Profile & Mechanism of Action
- Modality: E‑PDC (Enhanced Probody Drug Conjugate) — a next‑generation evolution of antibody–drug conjugate (ADC) technology
- Core Innovation — “Probody Technology”: A specialized molecular design keeps the antibody in an inactive “dormant state” in normal tissues, activating only within the tumor microenvironment
- Safety Advantage vs. Traditional ADCs: Significantly reduces off‑target toxicity and avoids damage to normal tissues — addressing a key limitation that has constrained ADC tolerability and dosing
- Development Status: LCUGZ1007 has completed systematic preclinical evaluation and is currently advancing optimization and translational research
Market Impact & Outlook
- Next Wave Beyond ADCs: Antibody–drug conjugates have become one of oncology’s hottest asset classes, but off‑target toxicity remains a leading cause of dose limitation and clinical failure. Tumor‑microenvironment‑activated probody designs are emerging as a differentiated next generation.
- Industry–Academia Industrialization: The RMB 19 million agreement pairs Liaocheng University’s research output with Shanghai Maiboxing Biotechnology’s development platform, targeting a full path from bench to industrialization.
- Clinical Timeline: With preclinical evaluation complete, the program’s stated objective is to enter clinical trials as soon as possible, positioning LCUGZ1007 among the early assets in the E‑PDC class.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding preclinical optimization, translational research, clinical trial entry, and industrialization of LCUGZ1007. Actual results may differ due to risks including research outcomes, regulatory timelines, funding, and competitive dynamics.-Fineline Info & Tech